[{"address1": "9669 Hermosa Avenue", "city": "Rancho Cucamonga", "state": "CA", "zip": "91730", "country": "United States", "phone": "619 596 8600", "fax": "619 596 8790", "website": "https://www.purebio.com", "industry": "Household & Personal Products", "sector": "Consumer Defensive", "longBusinessSummary": "PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILV\u00c9RION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.", "fullTimeEmployees": 11, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert F. Bartlett", "age": 78, "title": "President, CEO & Director", "yearBorn": 1945, "fiscalYear": 2023, "totalPay": 129800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark Stuart Elliott", "age": 48, "title": "VP of Finance and Principal Financial & Accounting Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 180000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas Richard Myers", "age": 70, "title": "Executive VP of Technology & Development and Director", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 200000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff  Kitchell", "title": "VP of Operations & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tim  Steffensmeier", "title": "Vice President of Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.0626, "open": 0.07, "dayLow": 0.0626, "dayHigh": 0.07, "regularMarketPreviousClose": 0.0626, "regularMarketOpen": 0.07, "regularMarketDayLow": 0.0626, "regularMarketDayHigh": 0.07, "beta": 0.086, "volume": 9000, "regularMarketVolume": 9000, "averageVolume": 22548, "averageVolume10days": 22620, "averageDailyVolume10Day": 22620, "bid": 0.0625, "ask": 0.0749, "marketCap": 6711360, "fiftyTwoWeekLow": 0.06, "fiftyTwoWeekHigh": 0.17, "priceToSalesTrailing12Months": 3.2096412, "fiftyDayAverage": 0.0704, "twoHundredDayAverage": 0.09395, "currency": "USD", "enterpriseValue": 8960215, "profitMargins": -1.7341, "floatShares": 66608293, "sharesOutstanding": 111856000, "sharesShort": 222969, "sharesShortPriorMonth": 254799, "sharesShortPreviousMonthDate": 1364428800, "dateShortInterest": 1367280000, "sharesPercentSharesOut": 0.0182, "heldPercentInsiders": 0.40452, "shortRatio": 2.56, "shortPercentOfFloat": 0.0186, "bookValue": -0.019, "lastFiscalYearEnd": 1690761600, "nextFiscalYearEnd": 1722384000, "mostRecentQuarter": 1714435200, "netIncomeToCommon": -3626000, "trailingEps": -0.04, "lastSplitFactor": "1:8", "lastSplitDate": 1344988800, "enterpriseToRevenue": 4.285, "enterpriseToEbitda": -2.913, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "PURE", "underlyingSymbol": "PURE", "shortName": "PURE Bioscience", "longName": "PURE Bioscience, Inc.", "firstTradeDateEpochUtc": 839511000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "514def58-2a10-331d-b6cb-5a547dd55cf6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.06, "recommendationKey": "none", "totalCash": 442000, "totalCashPerShare": 0.004, "ebitda": -3076000, "totalDebt": 2400000, "quickRatio": 1.015, "currentRatio": 1.305, "totalRevenue": 2091000, "revenuePerShare": 0.019, "returnOnAssets": -1.45818, "freeCashflow": -1558000, "operatingCashflow": -2682000, "revenueGrowth": 0.084, "grossMargins": 0.57293, "ebitdaMargins": -1.4710699, "operatingMargins": -1.85261, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-26"}]